ERAS Overview

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is5.50 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Erasca Inc revenue for the last quarter amounts to -37.91M USD, increased 6.40

Erasca Inc. EPS for the last quarter amounts to -27419000.00 USD, decreased -13.34

Erasca Inc (ERAS) has 103 emplpoyees as of May 31 2026.

Today ERAS has the market capitalization of 3.99B USD.